RxDoctor Payments Data

Mary Gindi, MD

Family Medicine · Danville, ILNPI 1417907031

Payments from drug & device makers

$13,657in general payments, 2019–2025

Across 625 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Bayer$903
  • Lilly USA, LLC$889
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$751
  • Novo Nordisk$736
  • plus $7K from 40 others

What the payments were for

  • Food & beverage$13,48199%
  • Education$1751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,657 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$1,444
Medicare patients
23
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol54$66,569
OzempicSemaglutide49$52,481
JardianceEmpagliflozin47$45,489
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$42,676
EliquisApixaban31$39,099
MounjaroTirzepatide14$18,983
LinzessLinaclotide13$13,013
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$10,972
JanuviaSitagliptin Phosphate11$8,988
Valsartan75$3,147
Atorvastatin Calcium264$2,698
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,897
Albuterol Sulfate HfaAlbuterol Sulfate65$1,742
Amlodipine Besylate214$1,684
Novolog FlexpenInsulin Aspart11$1,657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,972$77,54268 claims
Novo NordiskOzempic$736$52,48149 claims
Boehringer IngelheimJardiance$495$45,48947 claims
GSKTrelegy Ellipta$1,217$42,67646 claims
PfizerEliquis$443$39,09931 claims
Lilly USA, LLCMounjaro$889$18,98314 claims
AbbVieLinzess$611$13,01313 claims
MerckJanuvia$261$8,98811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Danville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →